Titan Medical Expands and Strengthens Global Intellectual Property Portfolio With Issuance of Robotic Surgery Patents
26 Março 2020 - 9:16AM
Business Wire
Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD)
(Nasdaq:TMDI), a medical device company focused on the design
and development of a single-port robotic surgical system for
application in minimally invasive surgery (“MIS”), announces that
its global intellectual property portfolio has increased to 49
issued patents and 86 patent applications, including the recent
granting and filing of patent applications directed at innovative
robotic surgery technologies.
Included in the recent patent grants is Japanese Patent No.
6,653,387 titled “Graphical User Interface for a Robotic Surgical
System,” which is directed at visual ways of interacting with
robotic surgery systems, including the Company’s single-port
robotic surgical system. The technology covered by this patent
provides instrument spatial position and related information to a
surgeon in a unique and user-friendly manner. Corresponding patent
applications are pending in the United States, China, Canada, South
Korea and Australia. The Australian patent application has been
allowed by the Australian Patent Office and the Company expects the
patent to be granted in the coming months.
Titan has also been granted U.S. Patent No. 10,532,466 and U.S.
Patent No. 10,568,707, each titled “Robotic Hand Controller,” which
are directed at aspects of hand controllers for use with robotic
surgery systems. These patents demonstrate the Company’s early
focus and success with the design of ergonomically advanced
components of robotic surgery systems. Titan has further advanced
these early ergonomic designs with the development of its
single-port robotic surgical system, including enhancing hand
controller design and functionality as described, for example, in
U.S. Patent No. 10,426,561 titled “Hand Controller Apparatus for
Detecting Input Position in a Robotic Surgery System.”
“The expansion of our global intellectual property portfolio
further strengthens Titan’s position as a leader in innovative
user-focused and ergonomically friendly single-port robotic surgery
technology,” commented David McNally, President and CEO of Titan
Medical. “The granting of these patents combined with previously
issued patents help position Titan as a pioneer in robotic surgery
technologies.
“While our initial focus for commercialization continues to be
the U.S., we remain committed to protecting our intellectual
property in major markets around the world to secure the long-term
value of the single-port surgical robotics opportunity for Titan or
any commercial partners. We are confident our system offers
advanced and ergonomically friendly technology in single-port
robotic surgery, which could ultimately play a substantial role in
expanding robotic surgery through greater access while improving
patient outcomes,” Mr. McNally added.
About Titan Medical Inc.
Titan Medical Inc. is focused on computer-assisted robotic
surgical technologies for application in MIS. The Company is
developing a single-port robotic surgical system comprised of a
surgeon-controlled patient cart that includes a dual-view camera
system with 3D and 2D high-definition vision options and
multi-articulating instruments for performing MIS procedures, and a
surgeon workstation that provides an advanced ergonomic interface
to the patient cart and a 3D endoscopic view inside the patient’s
body. Titan intends to initially pursue gynecologic surgical
indications for use of its single-port robotic surgical system.
For more information, please visit the Company’s website at
www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws. Such
statements reflect the current expectations of management of the
Company’s future growth, results of operations, performance and
business prospects and opportunities. Wherever possible, words such
as “may”, “would”, “could”, “will”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements reflect management’s current beliefs
with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions. Many
factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the Company’s Annual
Information Form dated March 29, 2019 (which may be viewed at
www.sedar.com).
Should one or more of these risks or uncertainties materialize,
or should assumptions underlying the forward-looking statements
prove incorrect, actual results, performance, or achievements may
vary materially from those expressed or implied by the
forward-looking statements contained in this news release. These
factors should be considered carefully, and prospective investors
should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in the news
release are based upon what management currently believes to be
reasonable assumptions, the Company cannot assure prospective
investors that actual results, performance or achievements will be
consistent with these forward-looking statements. Except as
required by law, the Company expressly disclaims any intention or
obligation to update or revise any forward-looking statements
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200326005332/en/
LHA Investor Relations Kim Sutton Golodetz (212) 838-3777
kgolodetz@lhai.com or Bruce Voss (310) 691-7100 bvoss@lhai.com
Titan Medical (NASDAQ:TMDI)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Titan Medical (NASDAQ:TMDI)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024